|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
TransMolecular, Inc.'s 131I-TM601 Successfully Localizes to Multiple Tumor Types without Targeting Healthy Tissue
6/17/2009 9:25:10 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc. today announced the presentation of data from a completed clinical study utilizing radiolabeled TM601, demonstrating highly specific tumor uptake of intravenously administered 131I-TM601 in several different primary and metastatic solid tumors, including glioma, melanoma, lung, prostate, colon, breast, and pancreatic cancers. Additionally, the study demonstrated that 131I-TM601 localized to tumors across the blood-brain barrier. The data were highlighted in an oral presentation at the Society for Nuclear Medicine (SNM) Annual Meeting. TM601 is a novel, wholly synthetic peptide found to have robust anti-angiogenic activity in neovascular diseases, including cancer and ophthalmic disease, as well as tumor-targeting capabilities.
|
|
|
|
|
|
|
|
|
|
|